Several other brokerages have also recently weighed in on DBVT. JMP Securities restated a “market outperform” rating and set a $4.00 target price on shares of DBV Technologies in a report on Tuesday, August 1st. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, August 1st. Finally, The Goldman Sachs Group cut their target price on DBV Technologies from $1.30 to $1.00 and set a “sell” rating for the company in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, DBV Technologies has a consensus rating of “Hold” and a consensus price target of $5.00.
DBV Technologies Stock Up 2.8 %
Institutional Trading of DBV Technologies
Several institutional investors have recently made changes to their positions in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of DBV Technologies during the 3rd quarter valued at approximately $94,000. Point72 Asset Management L.P. purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at approximately $5,914,000. Citadel Advisors LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at approximately $55,000. BlackRock Inc. raised its position in shares of DBV Technologies by 4.6% during the 2nd quarter. BlackRock Inc. now owns 1,017,670 shares of the company’s stock valued at $1,934,000 after buying an additional 44,414 shares during the period. Finally, Optiver Holding B.V. purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 23.90% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.
- Five stocks we like better than DBV Technologies
- What Are Dividend Champions? How to Invest in the Champions
- MarketBeat Week in Review – 11/6 – 11/10
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Data giants MongoDB and Snowflake just got upgraded
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.